Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
story of the week
Published in Von Hippel-Lindau Disease

Journal Scan / Research · November 27, 2019

Efficacy and Safety of TKIs for VHL Disease

Frontiers in Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Eric Jonasch MD

Jeremy Ross MD

Frontiers in Oncology
The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients
Front Oncol 2019 Nov 01;[EPub Ahead of Print], K Ma, B Hong, J Zhou, Y Gong, J Wang, S Liu, X Peng, B Zhou, J Zhang, H Xie, K Zhang, L Li, D Cai, Z Wang, L Cai, K Gong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated